BDBM562820 2-((2S,5R,6S)-4-((R)-1-(1H-Tetrazol-5-yl)butyl)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-oxomorpholin-2-yl)acetic acid and 2-((2R,5S,6R)-4-((S)-1-(1H-tetrazol-5-yl)butyl)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-oxomorpholin-2-yl)acetic acid or 2-((2S,5R,6S)-4-((S)-1-(1H-tetrazol-5-yl)butyl)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-oxomorpholin-2-yl)acetic acid and 2-((2R,5S,6R)-4-((R)-1-(1H-tetrazol-5-yl)butyl)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-oxomorpholin-2-yl)acetic acid::US11407721, Example 67

SMILES CCC[C@H](c1nnn[nH]1)N1C(=O)[C@@H](CC(=O)O)O[C@H](c2cccc(Cl)c2)[C@@H]1c1ccc(Cl)cc1

InChI Key InChIKey=AXLFRXXLVUJAFX-UHFFFAOYSA-N

Data  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 562820   

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandChemical structure of BindingDB Monomer ID 562820BDBM562820(US11407721, Example 67 | 2-((2S,5R,6S)-4-((R)-1-(1...)
Affinity DataIC50: 425nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandChemical structure of BindingDB Monomer ID 562820BDBM562820(US11407721, Example 67 | 2-((2S,5R,6S)-4-((R)-1-(1...)
Affinity DataIC50: 426nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
US Patent